Eisai Co Ltd Spons A (ESALY) 66.8500 $ESALY Eisai Co's

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 10:14 AM

Eisai Co Ltd Spons A (ESALY) 66.8500 $ESALY

Eisai Co's (ESALY) CEO Haruo Naito on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 7:26AM CDT

Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue May 12, 8:10AM CDT
Arena (ARNA) first quarter 2015 results were better-than-expected with the company posting a narrower loss and higher revenues.
GILD: 110.89 (+1.59), ARNA: 4.30 (+0.05)

Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 177.36 (-0.65), CNCE: 14.01 (-0.12), HPTX: 45.99 (+0.02)

Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu May 07, 3:00PM CDT
Arena (ARNA) will be reporting first quarter 2015 results on May 11.
IPXL: 44.41 (-0.03), ACT: 295.29 (-1.31), ARNA: 4.30 (+0.05)

Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 27, 1:40PM CDT
Epizyme, Inc. (EPZM), scheduled to report its first-quarter 2015 results on Apr 28, carries a Zacks Rank #3 with an Earnings ESP of +35.35%.
ACT: 295.29 (-1.31), EPZM: 17.60 (+0.17), EXEL: 3.32 (-0.05)

Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:09PM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced the completion of two phase I studies on their obesity drug, Belviq, being developed as a once-daily extended release formulation.
CYTK: 6.04 (+0.08), NVO: 56.59 (-0.16), ARNA: 4.30 (+0.05)

Arena Gets Closer On Extended Release Formulation Of Belviq
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 6:59AM CDT

ARNA: 4.30 (+0.05)

Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 392.34 (+1.10), SPHS: 0.64 (-0.01), ADMS: 17.89 (+0.05), TKMR: 13.91 (-0.03), CBYL: 7.86 (+0.16), HPTX: 45.99 (+0.02), QURE: 26.57 (+0.03), SHPG: 254.45 (unch), SRPT: 15.49 (+0.28), HZNP: 29.12 (+0.09), GALE: 1.33 (-0.02), JUNO: 41.95 (-1.42), ABBV: 65.66 (-0.33), CBMG: 30.00 (+2.50), ARNA: 4.30 (+0.05), EXEL: 3.32 (-0.05), ADXS: 19.96 (-0.12), PTLA: 37.33 (+0.12), BMY: 68.00 (+0.36), OCUL: 25.82 (-0.45), NVO: 56.59 (-0.16), DVA: 81.50 (+0.02), HALO: 16.56 (+0.14), GILD: 110.89 (+1.59), MRK: 60.29 (+0.06), AZN: 68.81 (-0.48), ALXN: 160.45 (-0.11), NVS: 103.96 (+0.21)

Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider
Spencer Osborne - at Seeking Alpha - Fri Apr 10, 9:27AM CDT

OREX: 4.94 (-0.07), ARNA: 4.30 (+0.05)

Arena completes two Phase 1 trials for once-daily formulation of Belviq
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:48AM CDT

ARNA: 4.30 (+0.05)

Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT

BIIB: 392.34 (+1.10), MDCO: 26.28 (-0.07), GILD: 110.89 (+1.59), MRK: 60.29 (+0.06), AZN: 68.81 (-0.48), LLY: 72.86 (-0.04), ABBV: 65.66 (-0.33), CELG: 115.51 (-0.02)

Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 9:00AM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced that the U.S. Patent and Trademark Office issued a new patent (U.S. Patent No. 8,999,970) to their obesity drug, Belviq.
CYTK: 6.04 (+0.08), NVO: 56.59 (-0.16), ARNA: 4.30 (+0.05)

Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 5:34PM CDT
Merck (MRK) entered into a collaboration with Syndax to evaluate Keytruda with the latter's entinostat for cancer therapy.
LCI: 53.35 (+0.75), MRK: 60.29 (+0.06), BMY: 68.00 (+0.36)

5 Freakishly Expensive Cancer Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 11:03AM CDT
The cost of cancer treatment is climbing, and healthcare advocates are increasingly worrying that skyrocketing cancer medication costs could take a big toll on the healthcare industry in the coming decade. A recent study conducted by the Memorial...
ESRX: 87.00 (-0.37), AMGN: 161.87 (-0.49), LLY: 72.86 (-0.04), NVS: 103.96 (+0.21)

Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 9:40AM CDT
Epizyme, Inc. (EPZM) reported fourth-quarter 2014 net loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
CYTK: 6.04 (+0.08), ANIP: 52.74 (+0.62), EPZM: 17.60 (+0.17)

Bad News For Pfizer's Chantix May Be Good News For Arena's Belviq
Spencer Osborne - at Seeking Alpha - Thu Mar 12, 4:34PM CDT

PFE: 34.00 (+0.01), ARNA: 4.30 (+0.05)

Eisai returns global rights to EZH2 program to Epizyme
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:00AM CDT

EPZM: 17.60 (+0.17)

Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To Be Fading
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:07AM CDT

OREX: 4.94 (-0.07), VVUS: 2.53 (+0.02), ARNA: 4.30 (+0.05)

Merck Inks Deal with Eisai for Cancer Combo Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 3:10PM CST
Merck (MRK) entered a deal with Eisai Co., Ltd. (ESALY) to put their various cancer drugs, Keytruda, Lenvima and Halaven through clinical testing for multiple cancer treatments.
MRK: 60.29 (+0.06), HZNP: 29.12 (+0.09), LLY: 72.86 (-0.04)

Merck and Eisai team up in cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:51AM CST

MRK: 60.29 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CopperWood Senior Living Revives Historic Campus

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Digital Art Sparks Future City Visions in Beijing

Beijing's Bold Digital Art Venture: A New Era in Creativity Ever felt the jittery buzz of innovation on the cutting edge? That's exactly what visitors experienced in Beijing's 'Spiritual Land: Future World of Inspiration' exhibition at the BOE Yiyun Digital Art Center. Set against the backdrop of the sprawling metropolis, this joint effort between Beijing and Linz aims to...

XREAL AURA: A New Era of Wired XR Glasses

Pioneering the XR Frontier Welcome to another day under the sun of cutting-edge tech, where XREAL's striking a chord with its new wired XR glasses—AURA. First off, don't let the tangled history of tech hype get to you. In the wild world of extended reality, we've seen plenty of flash, not enough substance. But XREAL's hitting the market with AURA, and I gotta say,...

Hershey's Sweet Results: 2026 Earnings Soar

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

DayOne's Bold Energy Moves With Sembcorp for Asia Growth

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Direxion Targets Anthropic's IPO with Bold New ETFs

Anthropic's IPO Sparks Direxion's Latest ETF Moves Alright, folks, Anthropic's public filing for an IPO isn't just turning heads—it's lighting up the trading floor! Following this buzz, Direxion grabs its chance to unleash two new ETFs designed to seize on Anthropic's rollercoaster debut. We're talking about the Direxion Daily Anthropic Bull 2X ETF (ANTO) and the...

GARDANT Expands Reach with International Partnership

GARDANT Global's Strategic Expansion Well, today we saw GARDANT Global make a move that screams ambition. They’re hooking up with International Offset Corporation (IOC) to muscle up their game in the murky waters of government procurement. Why does this matter? Because it's all about who gets the contracts, and with GARDANT’s newfound reach, they’re not just...